Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Top Cited Papers
- 1 December 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 444 (7122), 1032-1037
- https://doi.org/10.1038/nature05355
Abstract
Tumour growth requires accompanying expansion of the host vasculature, with tumour progression often correlated with vascular density. Vascular endothelial growth factor (VEGF) is the best-characterized inducer of tumour angiogenesis. We report that VEGF dynamically regulates tumour endothelial expression of Delta-like ligand 4 (Dll4), which was previously shown to be absolutely required for normal embryonic vascular development. To define Dll4 function in tumour angiogenesis, we manipulated this pathway in murine tumour models using several approaches. Here we show that blockade resulted in markedly increased tumour vascularity, associated with enhanced angiogenic sprouting and branching. Paradoxically, this increased vascularity was non-productive—as shown by poor perfusion and increased hypoxia, and most importantly, by decreased tumour growth—even for tumours resistant to anti-VEGF therapy. Thus, VEGF-induced Dll4 acts as a negative regulator of tumour angiogenesis; its blockade results in a striking uncoupling of tumour growth from vessel density, presenting a novel therapeutic approach even for tumours resistant to anti-VEGF therapies.Keywords
This publication has 29 references indexed in Scilit:
- Lessons from phase III clinical trials on anti-VEGF therapy for cancerNature Clinical Practice Oncology, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- VEGF Trap as a Novel Antiangiogenic Treatment Currently in Clinical Trials for Cancer and Eye Diseases, and VelociGene(R)- based Discovery of the Next Generation of Angiogenesis TargetsCold Spring Harbor Symposia on Quantitative Biology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Vascular Endothelial Growth Factor as a Target for Anticancer TherapyThe Oncologist, 2004
- VEGF-Trap: A VEGF blocker with potent antitumor effectsProceedings of the National Academy of Sciences of the United States of America, 2002
- Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy ApproachesCancer and Metastasis Reviews, 2001
- Vascular-specific growth factors and blood vessel formationNature, 2000